THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MaxCyte Inc.

("MaxCyte" or the "Company")

Result of Annual General Meeting

ROCKVILLE, Md., LONDON, UK, 19 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics today announces that at its Annual General Meeting held yesterday, all resolutions were duly passed.

The full text of the resolutions proposed and passed at the Annual General Meeting can be found in the proxy statement which was published and posted to stockholders on April 28, 2025 and copies of which are available in the SEC's EDGAR filing database on the SEC's website at www.sec.gov. 

AIM Delisting

Among the resolutions passed by stockholders was a resolution for the cancellation of the admission of the Company's Common Stock to trading on AIM. Accordingly, it is expected that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025.

Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.

Further information regarding the delisting, including arrangements for how investors can continue to trade the Company's Common Stock on Nasdaq and other 'frequently asked questions', can be found at: https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a

Maher Masoud, President and CEO of MaxCyte commented: "I would like to thank our shareholders for their support since the Company's AIM listing in 2016. The belief and continued commitment from our U.K. investors in our vision of enabling cell and gene therapies allowed us to have the foundation to become the only cell-engineering technology used in the engineering of a commercial non-viral gene edited product. While we will be a Nasdaq only listed company, all of our shareholders have my commitment to our continued engagement. Cell and gene therapies are the future of medicine, and with the continued support from our shareholders, MaxCyte's leading non-viral cell-engineering platform with SeQure's DX's gene editing risk assessment services will help drive precision medicine forward."

For further information, please contact:

Additional Information

The person responsible for arranging the release of this information on behalf of the Company is David Sandoval, General Counsel.

About MaxCyte

At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.